Clinical trial NCT06183814: A Study of EXG102-031 in Participants With wAMD
Official title: An Open-label, Dose-escalation Phase I/IIa Study to Evaluate the Safety and Efficacy of EXG102-031 Intraocular Injection in Participants With Neovascular Age-related Macular Degeneration（wAMD）
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Neovascular Age-related Macular Degeneration
Keywords: Wet Age-related Macular Degeneration
Lead sponsor: Hangzhou Jiayin Biotech Ltd
Sponsor class: INDUSTRY
First posted: 2023-12-28
Enrollment: 42
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Dose escalation
Primary purpose: TREATMENT

Brief summary: In neovascular (wet) age-related macular degeneration (wAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with wAMD.

Detailed description: Age-related macular degeneration (AMD) is a major cause of blindness and visual impairment in older adults. The wet form of AMD, also called neovascular AMD (nAMD) usually causes faster vision loss than the dry form. The most common current treatments of nAMD are products that inhibit vascular endothelial growth factor (VEGF) (including ranibizumab (LUCENTIS®, Genentech) and aflibercept (EYLEA®, Regeneron) and are delivered by intravitreal injections at 4 to 16 week intervals and continued indefinitely. This Open-label, Dose-escalation Phase I/IIa Study is designed to evaluate the safety and efficacy of EXG102-031 intraocular Injection in participants with wet(Neovascular) Age-related Macular Degeneration（wAMD）.

Eligibility criteria: Inclusion Criteria:

1. Male or female, age ≥ 50 years of age;
2. Diagnosis of wAMD and current active lesion in the study eye at Screening;
3. An ETDRS BCVA letter scores between 73 and 9 letters in the study eye;
4. Response to anti-VEGF treatment within 6 months prior to screening or at the time of screening introduction;
5. The study eye must be a Intraocular lens eye(post-cataract surgery status) and be at least 1 month post IOL implantation at enrollment;
6. Voluntarily agree to participate in the clinical trial, understand the trial procedures, and be capable of signing the informed consent form before screening.

Exclusion Criteria:

1. Presence of any ocular disease or history of disease in the study eye other than wAMD that may affect central visual acuity and/or macular detection;
2. Presence in the study eye of CNV or macular pathology pathography due to causes other than wAMD;
3. The study eye has severe and irreversible retinal structural damage involving the fovea (such as retinal pigment epithelial (RPE) atrophy, retinal fibrosis, laser scars, dense hard exudation); Or other retinal damage in the target eye that, in the opinion of the investigator, may impede visual improvement after resolution of macular edema ;
4. Subretinal hemorrhage accumulating the central fovea of the study eye, with an area of hemorrhage ≥ 4 optic disc diameters;
5. Presence of advanced glaucoma or uncontrolled ocular hypertension in the study eye;
6. Prior receipt of any ocular or systemic gene therapy agent.

Primary outcomes:
measure: Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)
timeFrame: 24 weeks following EXG102-031 administration
Secondary outcomes:
measure: Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)
timeFrame: 52 weeks following EXG102-031 administration
measure: Change From Baseline in BCVA (Best Corrected Visual Acuity)
timeFrame: 52 weeks following EXG102-031 administration
measure: Change From Baseline in CRT (Central Retinal Thickness)
timeFrame: 52 weeks following EXG102-031 administration
measure: Supplemental Injections (Annualized Rate of Supplemental Injections)
timeFrame: 52 weeks following EXG102-031 administration
Other outcomes:
Locations:
city: Peking
country: China
facility: Beijing Hospital
state: Beijing
city: Peking
country: China
facility: Beijing Tongren Hospital,Cmu
state: Beijing
city: Peking
country: China
facility: Peking University People'S Hospital
state: Beijing
city: Chongqing
country: China
facility: The Southwest Hospital of Amu
state: Chongqing
city: Wuhai
country: China
facility: Central theater General Hospital
state: Hubei
city: Nanjing
country: China
facility: Jiangsu Provinve Hospital
state: Jiangsu
city: Hangzhou
country: China
facility: The Second Affiliated Hospital Zhejiang University School of Medicine
state: Zhejiang
city: Wenzhou
country: China
facility: Eye Hospital,WMU
state: Zhejiang
Study officials:
affiliation: Peking University People's Hospital
name: Mingwei Zhao, PhD
role: PRINCIPAL_INVESTIGATOR
References: